© 2024 Alpha Spread Limited. All Rights Reserved.
www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.
You don't have any saved screeners yet
Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.
Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Haemonetics Corporation Fourth Quarter Fiscal 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions]
I would now like to hand the conference over to your speaker host for today, Olga Guyette, Senior Director of Investor Relations and Treasury. Please go ahead.
Good morning, everyone. Thank you for joining us for Haemonetics' Fourth Quarter Fiscal 2020 Conference Call and Webcast. I'm joined today by Chris Simon, our CEO; and James D’Arecca, our CFO.
This morning, we posted our fourth quarter fiscal '22 results to our Investor Relations website, along with our fiscal '23 guidance and the analytical tables with the information that we'll refer to on this call. Additionally, we provided a complete P&L, balance sheet, summary statement of cash flows as a reconciliations of our GAAP to non-GAAP financial results and guidance.
Before we get started, unless otherwise noted, all revenue growth rates discussed today are on an organic basis and exclude the impact of currency fluctuation, strategic exits of product lines, acquisitions and divestitures and the impact of the 53rd week in fiscal '21.
As in the past, we will refer to non-GAAP financial measures throughout to help investors understand Haemonetics' ongoing business performance. Please note that these measures exclude certain charges and income items. Please refer to this morning's earnings release for details on excluded items, including comparisons with the same periods of fiscal '21 and a reconciliation to our GAAP results.
Our remarks today include forward-looking statements, and our actual results may differ materially from the anticipated results. Haemonetics cautions that these forward-looking statements are subject to risks and uncertainties, including the potential impacts from the pandemic on our results and other factors referenced in the safe harbor statement in our earnings release and our filings with the SEC. We do not undertake any obligation to update these forward-looking statements.
And now I'd like to turn it over to Chris.
Thanks, Olga, and thank you all for joining our earnings call. Today, we reported organic revenue growth of 19% in the fourth quarter and 7% in fiscal '22, and an adjusted earnings per diluted share of $0.65 in the fourth quarter, and $2.58 in fiscal '22, an increase of 41% versus the prior year fourth quarter, and an increase of 10% versus the prior fiscal year.
The past year was a challenging one, but we are proud of how our people have responded. Our fourth quarter performance reflects our resilience and our commitment to meet the needs of our customers and deliver on our purpose of improving standards of care. Our agility and perseverance helped us achieve growth in all businesses, and we continue to distinguish Haemonetics for the meaningful value we are creating across our markets.
As the industry leader, we delivered integrated solutions to help our plasma customers realize much needed growth in the volume of collections. In the face of unprecedented blood shortages, our blood center products help maximize the impact of donations, and attract and retain donors. Hospital, including Vascular Closure, continue to exceed expectations and was our fastest-growing business in fiscal '22, helping customers improve patient care and outcomes at less cost.
As we evolve our portfolio and we expand our reach and relevance, Hospital will increasingly drive our growth and diversification. Our operational excellence program proved fundamental to our resilience and ability to quickly address supply chain disruptions, and serve all who depend on us. It will continue to play a critical role in sustaining our success, enabling us to be a more agile, efficient and productive company, creating lasting cost savings and bring resources to fund investments.
Turning now to our business unit results. Plasma revenue increased 31% in the fourth quarter driven by a 12% increase in U.S. plasma volume, price benefits and a $6 million stocking order. Excluding the stocking order, U.S. Plasma volume declined 4% sequentially, which compares favorably to a typical seasonal decline of about 7% in the fourth quarter, and last year's fourth quarter decline of 13%. In fiscal '22, Plasma revenue grew 10% driven by growth in volume. We remain committed to enabling our customers to improve donor satisfaction, maximize Plasma volume and lower cost per liter collected. Our technology and ongoing product development are essential to helping our customers meet these critical needs.
Nearly all of our major customers in the U.S. are now experiencing the full value of our technology through a network of bidirectionally connected NexSys PCS devices with NexLynk DMS and Donor360 app.
Working closely with our customers, we have designed NexSys to streamline the collection process. These advances have proven especially important at a time when our customers are facing unprecedented staffing challenges. Our fully integrated system plays a vital role in a positive donor experience and collection center productivity. From instant check-in upon arrival through streamlined donation and expedited payment, NexSys contributes to a demonstrated 16-minute reduction in average donor door-to-door times, improved compliance, including a 98% elimination of documentation errors and increased donor satisfaction. Our customers are also collecting an additional 9% to 12% of Plasma yield on average on NexSys with Persona, enabling them to both increase Plasma supply and reduce the average cost per liter.
We are leveraging extensive customer experience and real-world data from nearly 30 million NexSys collections to focus our ongoing innovation agenda. Our product development efforts continue to help customers improve center operations by driving growth in collections and improving Plasma volume output while increasing donor retention and satisfaction. We look forward to sharing more about these programs at our Investor Day in June.
The patient need for plasma-derived pharmaceuticals has never been greater. We continue to see long-term plasma market collections demand of 8% to 10%, and we expect to see volume growth in excess of that as fractionators strive to replenish depleted plasma inventories.
Moving to Hospital. Revenue increased 19% in the fourth quarter and 16% in fiscal '22. All 4 of our product lines grew this year despite the challenges posed by the Omicron outbreaks, Hospital staffing shortages and COVID-19-related lockdowns in China.
Hemostasis Management delivered 12% revenue growth in the quarter and 20% revenue growth in fiscal '22. In the U.S., our largest market, TEG, delivered robust growth both in the quarter and in fiscal '22. We also benefited from strong growth in Europe, primarily driven by successful market penetration with our ClotPro, viscoelastic elastic diagnostic device, which was acquired in April 2020.
Growth in the U.S. and Europe was partially offset by weaker sales in China. As you will hear during our Investor Day, we remain enthusiastic about our ability to grow organically and inorganically in what we estimate is a $700 million global market.
Transfusion Management revenue grew 18% in the fourth quarter and 11% in fiscal '22, and was equally strong for BloodTrack and for SafeTrace Tx as we completed a series of new account installations. Our fourth quarter results also benefited from a catch-up in software implementations in the U.S. after a few months of delay due to Omicron.
Cell salvage revenue increased 17% in the quarter and 8% in fiscal '22 driven by procedure recovery and strong capital sales. Growth in the quarter also benefited from back order relief, from the temporary supply chain constraints we experienced in the third quarter.
Vascular Closure continues to excel delivering a record $27 million of revenue in the fourth quarter and $94 million in fiscal '22. With the integration of this business essentially complete, our focus is on accelerating our penetration into the $2.8 billion underpenetrated market. While advancing our product portfolio to continue strengthening the role of our Hospital business as a growth engine for Haemonetics.
Blood Center revenue grew 7% in the fourth quarter and declined 1% in fiscal '22. Apheresis revenue declined 1% in the quarter and fiscal '22 as the strong recovery in platelet collections in Japan was offset by lower revenue from convalescent plasma, and staffing shortages that affect the collection centers across the U.S.
Whole Blood grew 26% in the quarter driven by favorable order timing among distributors in EMEA and additional opportunities in North America. Our supply chain resilience enabled us to serve customers in need. For the full year, Whole Blood revenue declined 3% driven by blood center staffing shortages and previously discontinued customer contracts in North America.
To carry our momentum into fiscal '23 and beyond, Haemonetics is set for robust transformational growth, propelled by investments in the advancement of our technologies and expansion of our global commercial capabilities. We look forward to sharing our updated long-range plans, key business initiatives, innovation agenda, and revised financial outlook at our Investor Day on Wednesday, June 29, at 10:00 a.m. Eastern Time, and we invite you to join us either in person, in Boston, or virtually.
I'll now turn the call over to James D’Arecca, and take this opportunity to welcome him as our new Executive Vice President and Chief Financial Officer. James brings to Haemonetics substantial experience and financial leadership from prominent global health care organizations, and I look forward to working together to support our company's growth, resource allocation and long-term value creation. James?
Thank you, Chris, and good morning, everyone. I'd like to begin by saying how excited I am to be part of Haemonetics. Tomorrow, we'll mark 1 month since I joined the company. And as I onboard, I'm incredibly impressed with our people, our leadership and the exciting possibilities ahead of us. I very much look forward to being part of this journey, and applying my experience towards growth and value creation.
Now let's discuss our business results and fiscal '23 guidance. Our results for the fourth quarter and fiscal '22 show continued resilience across the business. Chris already discussed our revenue results, so I will focus on the rest of the financials. Our adjusted gross margin was 53.6% in the fourth quarter and 53.9% in fiscal '22, an increase of 360 basis points when compared with the same periods of the prior year. The adjusted gross margin expansion was driven by the addition of the Vascular Closure business and benefits from the operational excellence program. These benefits were partially offset by inflationary pressures in our supply chain and manufacturing, including freight, labor and raw material costs as well as higher depreciation costs primarily related to the increasing installed base of our NexSys devices in the U.S.
Price had a positive impact on the fourth quarter results, but a limited impact on our fiscal '22 since price adjustments in our Plasma business in the first 9 months of the year largely offset price benefits from NexSys and Persona conversions in the second half of fiscal '22. As a reminder, these price adjustments were related to the expiration of fixed term pricing on historical PCS2 technology, and were fully annualized at the end of the third quarter of fiscal '22.
Adjusted operating expenses in the fourth quarter were $95.4 million, an increase of $13.4 million or 16% compared with the fourth quarter of the prior year. As a percentage of revenue, adjusted operating expenses decreased by 40 basis points to 36%. Adjusted operating expenses in the fourth quarter included a ramp-up in investments that were delayed earlier in fiscal '22. Adjusted operating expenses for fiscal '22 were $348.6 million, an increase of $65.6 million or 23% compared with the prior year.
As a percentage of revenue, adjusted operating expenses increased by 260 basis points to 35.1%. Vascular Closure had the largest impact on adjusted operating expenses in the quarter and in fiscal '22. Additionally, we had higher investments, higher outbound freight costs and increases in other expenses associated with the return to normal spending levels. Contributions from our productivity savings, lower variable compensation and the impact of the 53rd week in fiscal '21, helped offset some of the cost increases, both in the quarter and in fiscal '22.
As a result of changes in our adjusted gross margin and adjusted operating expenses, fourth quarter adjusted operating income was $46.6 million, an increase of $16.1 million or 53%, and adjusted operating income for fiscal '22 was $187.1 million, an increase of $32.6 million or 21% compared with the prior year. As a percentage of revenue, adjusted operating income margin was 17.6% in the fourth quarter and 18.8% in fiscal '22, up 410 basis points and [100] basis points, respectively compared with the same periods in fiscal '21.
The macroeconomic-driven inflationary environment continues to be challenging. The impacts in fiscal '22 have been broad-based, including freight, raw materials and labor. We estimate an approximately 300 basis point impact from inflationary pressures on our adjusted operating income margin. Our operational excellence program is an important lever in making us more efficient and agile, especially during periods of high macroeconomic uncertainty. In our fiscal '22, this program delivered $37 million of gross savings, freeing up resources to fund additional investments. Since the inception of this program, we have generated $71 million in cumulative gross savings, slightly ahead of our plan.
We also had positive contributions from Vascular Closure. This business continues to exceed our expectations. And within the first year of our ownership of this business, it has delivered a robust revenue growth and positive contribution to our adjusted earnings per diluted share compared with $0.15 to $0.20 of dilution we had originally guided to in the first year following the acquisition. We are excited about the opportunities in Vascular Closure, and we'll continue to allocate investments to fund its growth.
The adjusted income tax rate was 22% for both the fourth quarter and fiscal '22 compared with 12% and 14%, respectively, for the same periods of the prior year. The adjusted income tax rate in fiscal '21 was lower than fiscal '22 due to the benefit of higher share vestings and option exercises in fiscal '21, which did not recur in fiscal '22.
Fourth quarter adjusted net income was $33.5 million, up $9.6 million or 40%, and adjusted earnings per diluted share was $0.65, and 41% when compared with the fourth quarter of fiscal '21. Adjusted net income for fiscal '22 was $132.6 million, up $11.9 million or 10%, and adjusted earnings per diluted share was $2.58, up 10% when compared with the prior year.
Changes in the adjusted income tax rate, higher interest expense and FX had a negative $0.10 impact on the fourth quarter and a negative $0.31 impact on the full year adjusted earnings per diluted share when compared with the prior year.
Cash on hand at the end of the fourth quarter was $259 million, up $67 million since the beginning of the year. Free cash flow before restructuring and restructuring-related costs was $117 million compared with $99 million at the end of the last fiscal year. The higher free cash flow before restructuring and restructuring-related costs in fiscal '22 was mainly due to lower accounts payable, largely due to a $54 million payment for our compensation-related liability as part of the Cardiva Medical acquisition in fiscal '21.
We also had higher accounts receivable as revenue continued to recover from the effects of the pandemic and higher capital expenses primarily related to NexSys upgrades and the operational excellence program, partially offset by a decrease in inventory. We have enough NexSys PCS devices in the U.S. inventory to convert the remainder of our major customers with no impact to future cash flow.
Our current debt structure includes a $700 million credit facility. That matures in June 2023, with balloon payments starting in September 2022. At the end of the fourth quarter, total debt outstanding under the facility was $284 million, with no borrowings outstanding under the $350 million revolving credit line at the end of fiscal '22. We plan to refinance our credit facility before the balloon payments are due.
Additionally, we have $500 million in convertible notes that expire in March of 2026. Our EBITDA leverage ratio as calculated in accordance with the terms set forth in the company's existing credit agreement was $3.08 at the end of fiscal '22.
Now let's move on to our guidance. We expect total organic revenue growth of 6% to 10% in fiscal '23. We remain confident in our Plasma business, and expect Plasma revenue to grow 7% to 12% in fiscal '23 with price and volume both contributing meaningfully.
Additionally, our guidance includes an $88 million minimum purchase commitment from CSL compared with $102 million of revenue in fiscal '22. We are excited about the opportunity in our Hospital business. Our go-to-market strategies are working, and we're looking forward to another year of strong commercial performance. In fiscal '23, we expect the Hospital business to deliver revenue growth of 16% to 19% driven by continued robust growth in Hemostasis Management and Vascular Closure.
Our Blood Center revenue guidance is a year-over-year decline of 4% to 7% and reflects additional geopolitical risk and an unfavorable impact from distributor order timing when compared with fiscal '22. We expect fiscal '23 adjusted operating margins in the range of 18% to 19%. Our adjusted operating margin guidance includes higher operating expenses driven by continuous investment into our business as we broaden our product portfolio to strengthen our technology and expand our commercial footprint and a return to normalized spending levels.
Our adjusted operating income margin also includes about 250 basis points of additional headwinds due to inflation and geopolitical risk. We expect our operational excellence program to deliver additional gross savings of approximately $22 million, with total cumulative savings reaching $93 million by the end of our fiscal '23. About half of these savings will be in cost of goods sold, with the rest in operating expenses, helping us generate additional efficiency across our business.
Our adjusted earnings per diluted share guidance for fiscal '23 is a range of $2.50 to $2.90. The midpoint of our adjusted earnings per diluted share guidance includes about $0.09 headwind from FX and share count. Additionally, consistent with our fiscal '22 results, we expect our adjusted earnings per diluted share to be higher in the second half of fiscal '23.
And lastly, our free cash flow before restructuring and turnaround expenses in fiscal '23 is expected to be $100 million to $130 million. Our capital allocation priorities remain unchanged, and we will continue to allocate capital to prioritize organic investments followed by inorganic opportunities and share repurchases.
Before we open the call up for Q&A, I wanted to reiterate the key points that we hope you takeaway from today's call. First, we continue to strengthen and grow our business despite the continued challenges caused by the pandemic. The end market demand, particularly for our Plasma and Hospital products is strong, and we're focused on maintaining an uninterrupted supply of our products.
Second, our product portfolio continues to evolve and increase our reach within large, underserved and fast-growing markets. The acquisition of Cardiva Medical was an important step in our transformational growth journey. We remain focused on further optimizing our portfolio and accelerating our growth.
Third, our operational excellence program improves our operating performance, enabling us to respond quickly to supply chain disruptions. We made significant progress by achieving more than half of the target program gross savings by the end of fiscal '22 while managing through a series of macroeconomic-driven headwinds. We plan to achieve the remaining $44 million to $54 million in target savings by the end of fiscal '25. This program is essential for our ongoing transformation. And once the macro environment stabilizes, these efficiency benefits will continue to expand our margins.
And finally, we remain committed to driving value for our customers and our shareholders. We are proud of the work we've done to meet the challenges over the past few years. We recognize more challenges are ahead, and we remain committed to taking action, implementing necessary changes and mitigating impacts without compromising growth of our business.
We look forward to sharing more detail about our plans to deliver value at our Investor Day. Thank you. And now I would like to open the line for Q&A.
[Operator Instructions] And our first question coming from the line of Larry Solow with CJS Securities.
Welcome James to Haemonetics. First question, I guess, just on the guidance range. It's a fairly wide range. Just trying to decipher the major disparities sort of -- not everything, probably a long list, but sort of between the low end and the high end, how would sort of get to that $290 million versus that $250 million?
It's Chris. Let me get to start, and I'll invite James to comment as well. First and foremost, it has to do with revenue, right? And we we're dependent upon our customers who are doing everything within their power to drive both donations and procedures. We saw meaningful recovery in the fourth quarter of our fiscal year. We expect that to continue through the year, but it's -- as you can appreciate, the last 8 quarters, particularly in Plasma and Blood Center have been difficult to forecast. So we want to be cautious there.
There's also a series of macro challenges that James had highlighted in the prepared remarks. We look at a combination of inflation, supply chain disruption, potentially, and then geopolitical risk, particularly in markets like China and Russia as potential headwinds in the overlay FX some other factors. It's a turbulent environment, and we just want to be mindful of that and reflect that with a wider range that we obviously will look forward to narrowing as we get further in the year, and some of these externalities play out.
Okay. And just in terms of your operating margin, it looks like relatively flat year-over-year. And just -- can we just speak to I guess the moving parts to that -- a couple of questions there. Gross margin is that -- it has been trending upwards. It doesn't sound like you're losing a lot of this to CSL revenue this year. So I guess maybe I'll absorb that next year. How do you view sort of gross margin? I know there's a lot of moving parts inflation, maybe getting a little bit worse for you guys. And then you also mentioned just part that question on the operational excellence program, $22 million in savings, half of that going back into gross margin. Are you spending the other half in operating expenses? Is that what I heard? Or will some of that actually flow to the bottom line?
Yes. Thanks, Larry. So yes, on the gross margins, we do expect those to improve slightly. What's benefiting them. I think you brought it up is price and mix, of course, to Cardiva as well as our operational excellence programs. What takes us back the other way, however, but not as much, is depreciation from the NexSys systems as well as the inflationary headwinds that we've spoken about, along with some negative FX in there. So those would be sort of the levers that we're looking at to affect gross margins. And then that obviously has an impact on operating margin as well. Yes. So you're right on the $22 million, it's roughly half to cost of goods savings, the other half going to OpEx.
In terms of -- we will be making some investments next year on the S&M line and the R&D line, so not all of that drops through. And we're also keeping a careful eye on the geopolitical risk as well as inflation. So I think once you net through all of that that's how the operating margins are essentially flat, and it could skew either way based on where the world turns as we go through the remainder of '22 into '23.
Yes. Got you. So I mean a lot of moving parts. Okay.
Our next question coming from the line of Drew Ranieri with Morgan Stanley.
Maybe just first on VASCADE. You've had the asset for a year now. Just curious how you're thinking about maybe the growth opportunity here in front of you, if you could lay out a number? I mean it looks like Hospital pre-VASCADE might have been growing high single digits. So is the right way to think about VASCADE is adding maybe 10 points to your Hospital growth? Just any help would be appreciated.
Yes. Drew, I appreciate the question. We're excited by what Hospital as a business is contributing, and will continue to contribute, right? We -- as a business, we're forecasting high teens, 16% to 19%, which is a continuation of where the combined business was in FY '22. Obviously, the 2 big drivers there are Hemostasis Management, the TEG franchise, and VASCADE as you highlight. We expect Hemostasis Management's performance to rival what it did in '22, which is great given the larger base.
And then VASCADE. VASCADE is exciting, right? We'll continue to focus primarily on the U.S. market. We're building out our plans for international expansion, both clinically from a regulatory perspective and our sales presence. But this year, FY '23, again, will be defined by further penetration into those top 500 or 600 electrophysiology hospitals here in the U.S.
Got it. And then just maybe on Plasma recovery. Can you give a little bit more details on what you're seeing in the market just as customers are trying to work through VASCADE cost for donor fees? Just maybe what you're seeing? And then with just the CSL revenue, I think I heard you say $88 million for fiscal 2023. Just curious about the cadence there. Should that be kind of a ratable basis across the quarters? Or is there any weighting that we should be thinking about?
Yes. Thanks, Jim. So clearly, Plasma is in recovery. It's been long coming. But I think you hear that from our customers as they're speaking publicly about this, we certainly saw that in our fourth quarter. Typically, the fiscal fourth quarter is the weakest quarter of the year in term of collection volumes, just given a bunch of seasonality, we expect to build from that, and that's what's reflected in our guidance, essentially building throughout the course of the year, culminating with the winter holidays. So we feel about that.
Clearly, it looks different than it has historically, more coming from new center openings, a disproportionate share of that growth. And that's a testament to the hard work that our customers are doing. They haven't backed off their pace of new center openings as fast as it has ever been, and they continue to do what they can to recruit and retain their donor base. So we stand ready to serve them. The great news is we have the devices, they're ready to go, and we're well on track for our conversions, both to NexSys and to Persona.
So we feel good about it. Obviously, there's factors that FY '22 is challenging in that regard. We think '23 will be different and better. We want to be cautious, which I know you can appreciate after 8 quarters of trying to forecast this, probably caution the operative term here.
Our next question coming from the line of Andrew Cooper with Raymond James.
Maybe first, I just want to get a better sense when we think about the last guide. Can you give us a little bit more flavor of -- how to comment on the fractionators time to make up some of that safety stock and maybe growing volumes faster than 8% to 10% in the near term. What's really reflected in the guidance there? That would be the first one. And then I'll ask one more after that.
Yes. Andrew, it's Chris. So what we experienced in our fiscal '22 was essentially 10% growth across the network, maybe a touch higher than that in North America and a touch below that outside the U.S. So if you think about that 10% growth in volume, we expect '23 will -- at the high end of our range, we'll replicate that. There's things that can be done above and beyond that. We made comments in my prepared remarks that we still see the underlying demand for IG at unprecedented level. So I think 6% to 8% demand for IG, that translates due to a number of factors we've outlined in the past 8% to 10% long-term growth in collections. And we know that our customers -- and we are committed to helping them gain inventory to get off of this incredibly low base that they're operating at today. So we would expect double-digit growth on top of that. And we just need for the various economic and societal factors to line up to enable them to do that. But we're in a good position to support it, and we think it grows over the course of the year. We'll look forward to updating and focusing that guidance as we watch the recovery unfolds.
Okay. Helpful. And then maybe just to sneak [too] in together here, but can you give us a better sense for sort of where specifically you are in the rollout of NexSys and Persona in terms of how many of the folks that are adding NexSys either have or are planning to add Persona? And how we should think about that? And then lastly, you made a comment about broadening the portfolio and have talked about innovation. So anything you can kind of give us some hint stores as to where new products might be and what -- how the portfolio might expand would be helpful as well?
Yes. So as we think about kind of the build-out and where we're going with collection volumes. It's something that we'll see unfold. I think it's a combination, as I've said before, about new center openings and recovery, hopefully, in the existing centers. That builds gradually over the course of the year. For us, we've got essentially everything contracted at this point, and we still believe we will have completed the NexSys PCS device rollout by the middle of our fiscal '23. So end of summer, early fall.
In terms of Persona, what's included in our guidance is the pricing benefits of everything that is already contracted. So we're not introducing any risk in terms of contracts beyond where we are. Obviously, it's a very powerful technology, 9% to 12% yield. It's the only thing like it in the market today. And we think -- when we look at the early adopters of the NexSys platform, so they've got NexLynk, they have the PCS device, and then they also have Persona. Those customers in our fiscal fourth quarter collected more Plasma than they had in any other prior quarter. So -- and I'm talking now back prior to the pandemic. It's a powerful enabler of what they're very keen to do in terms of accelerating their growth rates.
So we think that will build, but it comes with some challenges. It's a larger bottle. They have to make logistical changes. Some of our customers are feeling compelled to validate the protein concentration, which we'll work with them to do clinically as we have in our regulatory filings. So yes, it takes a bit of time, and hopefully get more clarity as the year goes forward. But it's an exciting technology, and we're seeing that in the marketplace.
You asked about portfolio evolution. I think as we've said, right, our capital allocation priorities really focused primarily on growth, both organic and inorganic. We've seen the additions we've made to the hospital portfolio. We now feel very good about our focus in cardiovascular, specifically electrophysiology and interventional cardiology. There's good convergence there. We think it's a target-rich opportunity set for us. And hopefully, you have a chance to talk more about it at the Investor Day in June where we'll outline our priorities, and how we're pursuing it.
[Operator Instructions] Our next question is coming from the line of Mike Matson with Needham & Company.
So I appreciate you breaking out the CSL revenue that you're expecting in '23. What should we be assuming in, if any, in '24, should we assume that it's largely done heading into fiscal '24?
Yes. Mike, we're not -- I think we've just given the guidance in the last hour on '23. I'm going to reserve comment on '24 until we get a little closer. But obviously, we stand ready to serve all of our customers. We did think the breakout is helpful just so you could see at '22 versus FY '23, but -- and then when we talk more at Investor Day. We'll be very clear over the next 4 or 5 years, how that growth trend line continues. And I think you'll be appropriately impressed with the organic capability of that business to scale and grow profitably.
Yes. Sorry, I guess I was talking specifically about CSL within the Plasma business I mean if you're not willing to answer, I understand because it isn't more than a year away. So...
Yes. I think we'll -- as we get closer, there's a bunch of things we don't have visibility into or don't control. Obviously, we'll serve CSL and all of our customers to the best of our ability within the existing agreements, which do go out, in CSL's case, through December of '23.
Okay. All right. And then I wanted to ask about this debt refinancing. You went through it kind of quickly. So I just want to make sure I understand the timing, the amount. And is there a risk here that, that results in higher interest expense, just given that rates have surged lately?
Yes. So thanks, Mike. Yes. The debt will be -- we'll look to refinance the debt in some way over the next quarter or so. I think it will look an awful lot like the end result of that will look an awful lot like it does today. With regards to interest rates, we do have interest rate swap coverage on 70% of the debt, which is now -- it's floating rate debt, it's been swapped to fixed. And we're covered there to 4% all the way through June of '23. So at that point in time, which seems a long time away. We'll see where the rates are and we'll look to see whether or not we want to re-up. But at the moment, we are not forecasting any increase in interest expense related to our refi activities.
Okay. Got it. And then just on the operational excellence savings, the $37 million of gross savings. I think that was for last fiscal year. What was the net savings, if it was $37 million gross?
Yes. So we don't break out gross versus net savings. We've -- on the -- to get you though to just give you some color, we certainly had made some investments in the business, plus there was some offsets during the year because of the inflationary headwinds, which took back some of that. And as we move forward, I think we'll see some of the same things as we -- our guidance assumes an additional savings next year. But then as I talked about earlier with regard to operating margins, there's some pieces that take it back as we make investments in S&M and R&D as we move forward.
And our next question coming from the line of David Turkaly from JMP Securities.
I apologize. I was coming on a couple of calls, but Chris, I wanted to see if you -- did you guys make any comments about the Terumo device, I know it's still very early. I don't know if it's out anywhere, but any of the features or -- obviously, we know CSL is there. But I kind of looked at your device thinking, hey, you can't really collect too much more from somebody or do it faster. So I'd just love to get your thoughts on sort of what it is or if anyone has seen it, or where it kind of stands today?
Yes. Mike -- Dave, I appreciate the question. It's -- I think folks were a little surprised how little information is out there, right? Obviously, we pay close attention to this. My understanding, having studied with our teams, the publications on the dot gov site, the -- got the device approved with a trial size of 124 donations. And kind of hard to draw a bunch of conclusions from that. We did over 20,000 donations to get Persona approved 2 years ago. They didn't publish anything on yield. We kind of piece together the metrics we assume, and it's an assumption that it was approximately 830 milliliters per collection. Obviously, we're well above that, right? And we've now got -- as we mentioned in the call, 30 million -- nearly 30 million NexSys donations, right? We stand behind the value proposition on the integrated NexSys platform. It is easy to use and set up, and that leads to a safe collection as evidenced by the 98% elimination of documentation errors and an impeccable safety record.
Donors like the device. They express a 93% affinity for NexSys. Donor satisfaction leads to more frequent donations and greater retention, which is absolutely key to the recovery we've been talking about. And then we've got good quantifiable evidence created with real-world work with our existing customers that NexSys lowers the cost to collect the liter of Plasma. And that's a combination of the 9% to 12% yield coupled with speeding up door-to-door time 16 minutes on average in our work with NexSys in the base configuration. So it's a good value proposition. We are building on that value proposition. I encourage you to come the team here in Boston when we do the Investor Day in June because we're going to unveil additional aspects of our innovation agenda, where we will further improve upon every one of those dimensions going forward. So excited. It's our platform, and it's doing good things with customers to support their growth aspirations. So feel good about it.
Yes. I appreciate that. And maybe just as a quick follow-up. I know Blood Center, certainly not a growth driver or a super important sort of part of probably the future of Haemonetics. But a decent quarter. I'd love to just get your thoughts on -- does that bottom at some point? Is it something that strategically is still an important part of sort of the go-forward plans? Or -- could it flatten out? Or -- I mean I know your guidance is calling for another whatever mid-single-digit decline, but does that stop at some point?
Dave, we care deeply about our Blood Center business and the customers we serve there. And yes, they had a very good quarter. In fact, they had a very good year overall relative to our initial expectations. And no small part, that was because our teams were able to step up, aided by our operational excellence program, right? We talk about the gross to net savings, and that's important. We want to free up resources to reinvest in growth, typically in other franchises. But what we also get from that OEP program is meaningful agility and resilience, not to mention the highest possible levels of product quality.
We benefited in the quarter and in the year in that blood center business, we were able to step in and meet customer demands, large stocking orders in some cases, as a contingency. In other cases where maybe their existing source of supply had let them down. So we were able to step in and fill that, and that bodes well. The guidance we gave a fairly wide range and down again, reflects disproportionately geopolitical risk, and some potential headwinds in FX. That business is concentrated outside the U.S. And we have some exposure there that we have to be mindful of. But we think it's actually increasingly stable and a good source of continued EBITDA for the company.
And I'm not showing anyone else in queue at this time. Ladies and gentlemen, that does conclude our conference for today, and thank you for your participation. You may now disconnect. Everyone, have a great day.